Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 9/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27558537 | 0.82 | PGR (0.56) | ALDH1A1RAB9AHPGDHTTNPC1 | |
| SCHEMBL3970818 | 0.81 | PGR (0.39) | ALDH1A1RAB9AHPGDHTTHRH3 | |
| SCHEMBL7381990 | 0.79 | MEN1 (0.34) | ALDH1A1HTTTAS1R3TAS1R1PGR | |
| SCHEMBL3329577 | 0.79 | CA2 (0.61) | — | |
| SCHEMBL19296965 | 0.77 | MLYCD (0.59) | ALDH1A1HPGDHRH3LMNA | |
| SCHEMBL8227509 | 0.74 | THRA (0.49) | ALDH1A1HPGDLMNA | |
| Hydrochloric Acid SCHEMBL11263668 | 0.74 | KMT2A (0.55) | ALDH1A1RAB9AHTTNPC1LMNA | |
| SCHEMBL27745008 | 0.73 | HTT (0.47) | ALDH1A1RAB9AHPGDHTTFOLH1 | |
| SCHEMBL8227512 | 0.71 | RAB9A (0.41) | ALDH1A1RAB9AHPGDHRH3NPC1 | |
| SCHEMBL14786715 | 0.71 | TAS1R3 (0.43) | RAB9AHTTFOLH1NPC1TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110123602-A1 | MOLECULAR LYMPHATIC MAPPING OF SENTINEL LYMPH NODES | HOON DAVE S B | 2011-05-26 | — | — | US | disclosed |
| US-7897336-B2 | Using a dye or radioactive tracer in conjunction with nucleic acid marker; cancer diagnosis and prognosis; drug delivery, gene therapy, activation of tumor immunity and inhibiting metastasis | JOHN WAYNE CANCER INSTITUTE (US) | 2011-03-01 | — | — | US | disclosed |
| EP-1594504-A4 | NOVEL IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND USES THEREOF FOR THERAPY AND DIAGNOSIS | T K SIGNAL LTD (IL) | 2008-12-17 | — | — | EP | disclosed |
| US-20060251574-A1 | HSP90 ligand selected from purines, ansamycins, radicicol, zearalanols, ATP analogs, indoles, chalcones, and benzimidazoles, derivatized with an imaging agent, radioactive material, or cytotoxic agent; preferably a geldanamycin derivatized with a radionuclide | CONFORMA THERAPEUTICS CORPORATION | 2006-11-09 | — | — | US | disclosed |
| EP-1560924-A4 | MOLECULAR LYMPHATIC MAPPING OF SENTINEL LYMPH NODES | WAYNE JOHN CANCER INST (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20060025430-A1 | Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis | T.K. SIGNAL LTD. (IL) | 2006-02-02 | — | — | US | disclosed |
| EP-1594504-A2 | NOVEL IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND USES THEREOF FOR THERAPY AND DIAGNOSIS | T.K. Signal Ltd. (IL) | 2005-11-16 | — | — | EP | disclosed |
| EP-1560924-A2 | MOLECULAR LYMPHATIC MAPPING OF SENTINEL LYMPH NODES | John Wayne Cancer Institute (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20050142556-A1 | Molecular lymphatic mapping of sentinel lymph nodes | JOHN WAYNE CANCER INSTITUTE | 2005-06-30 | — | — | US | disclosed |
| US-6815170-B1 | FOR PROGNOSIS/DIAGNOSIS/THERAPY OF CANCERS USING CARBON BLACK ADMINISTRATION AND DETECTING ACCUMULATION IN TUMOR TISSUES | JOHN WAYNE CANCER INSTITUTE | 2004-11-09 | — | — | US | disclosed |
| WO-2004064718-A2 | IRREVERSIBLE INHIBITORS OF EGF RECEPTOR TYROSINE KINASES AND USES THEREOF | T.K. SIGNAL LTD. (IL) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004016154-A2 | MOLECULAR LYMPHATIC MAPPING OF SENTINEL LYMPH NODES | JOHN WAYNE CANCER INSTITUTE (US) | 2004-02-26 | — | — | WO | disclosed |
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | DRUG INNOVATION & DESIGN, INC. | 2003-07-24 | — | — | US | disclosed |
| EP-1255567-A1 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | Drug Innovation & Design, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001036003-A2 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | DRUG INNOVATION & DESIGN, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
| US-5919934-A | BISAMINOTHIOL AND AMINO COMPOUNDS WITH APPENDED PHARMACOPHORES, METAL COMPLEXES OF THESE COMPOUNDS; | THE GEORGE WASHINGTON UNIVERSITY (US) | 1999-07-06 | — | — | US | disclosed |
| US-5911970-A | ANTITUMOR AGENTS AND ANTICARCINOGENIC AGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1999-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060251574-A1 | HSP90 ligand selected from purines, ansamycins, radicicol, zearalanols, ATP analogs, indoles, chalcones, and benzimidazoles, derivatized with an imaging agent, radioactive material, or cytotoxic agent; preferably a geldanamycin derivatized with a radionuclide | HSP90B1, CDC37, HSP90AB1 | ALDH1A1 1481/4885RAB9A 1650/4885HPGD 1009/4885 |
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | PAICS, ABCB1, ABCG2 | ALDH1A1 589/4885RAB9A 2022/4885HPGD 1238/4885 |
| US-20060025430-A1 | Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis | EGFR, ERBB2, ERBB3 | ALDH1A1 3537/4885RAB9A 2043/4885HPGD 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.